Cholesgen (Shanghai) Co. Ltd. develops novel therapeutics targeting metabolic diseases and tumors by utilizing a proprietary drug discovery platform that integrates reporter gene screening, protein-small molecule interaction systems, and in vitro drug efficacy testing. The company addresses the critical need for effective treatments for conditions such as hyperlipidemia, obesity, diabetes, and atherosclerosis, leveraging unique biochemical and clinical insights to optimize drug development.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for metabolic diseases and tumors, such as hyperlipidemia, obesity, diabetes, and atherosclerosis, often exhibit limited efficacy or significant side effects. There is a need for innovative therapeutic approaches that target the underlying mechanisms of these complex conditions.
Solution
Cholesgen (Shanghai) Co. Ltd. is a biopharmaceutical company focused on developing novel therapeutics for metabolic diseases and tumors. The company utilizes a proprietary drug discovery platform integrating reporter gene screening, protein-small molecule interaction systems, and in vitro drug efficacy testing to identify and optimize drug candidates. Cholesgen focuses on novel targets and leverages expertise in biochemistry, disease biology, medicinal chemistry, and clinical translational medicine to build a differentiated pipeline. The company aims to address unmet medical needs by developing innovative drugs based on new mechanisms of action.
Target Audience
The primary target audience includes patients suffering from metabolic diseases (such as hyperlipidemia, obesity, and diabetes) and cancer, as well as healthcare providers seeking more effective treatment options.
Features
- Proprietary drug discovery platform integrating reporter gene screening, protein-small molecule interaction systems, and in vitro drug efficacy testing
- Focus on novel targets in cholesterol metabolism and related pathways
- Development of small molecule therapeutics for hyperlipidemia, obesity, diabetes, atherosclerosis, and NASH
- Expertise in biochemistry, disease biology, medicinal chemistry, and clinical translational medicine